资源预览内容
第1页 / 共44页
第2页 / 共44页
第3页 / 共44页
第4页 / 共44页
第5页 / 共44页
第6页 / 共44页
第7页 / 共44页
第8页 / 共44页
第9页 / 共44页
第10页 / 共44页
亲,该文档总共44页,到这儿已超出免费预览范围,如果喜欢就下载吧!
资源描述
PREFACEThisdocumentistheDMIDprotocoltemplate,whichisrequiredfordevelopingDMID-sponsoredclinicalresearchprotocols.Notethatinstructionsandexplanatorytextareindicatedbyitalicsandshouldbereplacedinyourprotocoldocumentwithappropriateprotocol-specifictext.Sectionheadingsandtemplatetextformattedinregulartypeshouldbeincludedinyourprotocoldocumentasprovidedinthetemplate.Thistemplateattemptstoprovideageneralformatapplicabletoallclinicaltrialsevaluatinganinvestigationalproduct.Wherespecificexamplesareprovided,theyareoftenfromthevaccinearea.ReferquestionsregardinguseofthisprotocoltemplatetotheappropriateDMIDProtocolChampionorClinicalAffairsSpecialist.TITLEDMIDProtocolNumber:DMIDFundingMechanism:(e.g.,grant#,contract#)PharmaceuticalSupportProvidedby:(ifapplicable)OtherIdentifyingNumbers:INDSponsor:(if即plicable)PrincipalInvestigator:DMIDProtocolChampion:DMIDMedicalMonitor:DMIDClinicalAffairsSpecialist:DMIDRegulatoryAffairsSpecialist:(if即plicable)DraftorVersionNumber:(seeDMIDSOPforassigningversionnumbers)DayMonthYear(Writeoutthemonthanduseinternationaldateformat,e.g.,23January2004)ThistemplateisadaptedfromtheICHguidancedocumentE6(GoodClinicalPractices),Section6.StatementofComplianeeProvideastatementthatthetrialwillbeconductedincomplianeewiththeprotocol,InternationalConferenceonHarmonisationGoodClinicalPracticeE6(ICH-GCP)andtheapplicableregulatoryrequirements.Usetheapplicableregulationsandrequirementsdependingonstudylocationandsponsorrequirements.Examplesofrequirementsthatarepotentiallyapplicableinclude:?U.S.CodeofFederalRegulationsapplicabletoclinicalstudies(45CFR46and21CFRincludingparts50and56concerninginformedconsentandIRBregulations,ifunderIND,21CFR312).?Directive9115071EEC:TheRulesGoverningMedicinalProductsintheEuropeanCommunity.?CompletionofHumanSubjectsProtectionTrainingReferto:http:/grants.nih.gov/grants/guide/notice-files/NOT-OD-01-061.htmlhttp:/69.5433/cO1/*NIHClinicalTermsofAwardSIGNATUREPAGEThesignaturebelowconstitutestheapprovalofthisprotocolandtheattachments,andprovidesthenecessaryassurancesthatthistrialwillbeconductedaccordingtoallstipulationsoftheprotocol,includingallstatementsregardingconfidentiality,andaccordingtolocallegalandregulatoryrequirementsandapplicableU.S.federalregulationsandICHguidelines.TheLeadPI,thePIsfromallparticipatingclinicalsitesandotherkeypartiesshouldsignthesignaturepageasappropriate.PrincipalInvestigator:Signed:Date:NameTitle1.1.1 StatementofComplianceiSignaturePageiiListofAbbreviationsviProtocolSummaryviiiKeyRoles1BackgroundInformationandScientificRationale3BackgroundInformation3Rationale3PotentialRisksandBenefits3PotentialRisks3KnownPotentialBenefits3Objectives4StudyDesign5StudyPopulation6SubjectInclusionCriteria7SubjectExclusionCriteria7Enrollment/Randomization/MaskingProcedures8StudyProcedures/Evaluations9ClinicalEvaluations9ConcomitantMedications/Treatments9LaboratoryEvaluations10ClinicalLaboratoryEvaluations10SpecialAssaysorProcedures10SpecimenPreparation,HandlingandShipping10Substudies11StudySchedule12Screening12Enrollment/Baseline12Follow-up13FinalStudyVisit13EarlyTerminationVisit13StudyIntervention/InvestigationalProduct14StudyProductAcquisition14Formulation,PackagingandLabeling14ProductStorageandStability14Preparation,AdministrationandDosageofStudyIntervention/InvestigationalProduct14AccountabilityProceduresfortheStudyIntervention/InvestigationalProduct(s).14AssessmentofSubjectCompliancewithStudyIntervention/InvestigationalProduct15AssessmentofScientificObjectives(e.g.,SafetyorImmunogenicityorEfficacy)16SpecificationoftheAppropriateOutcomeMeasures16PrimaryOutcomeMeasures16SecondaryOutcomeMeasures16MethodsandTimingforAssessing,Recording,andAnalyzingAppropriateOutcomeMeasures16ModificationandDiscontinuationofStudyIntervention/InvestigationalProductforaParticipant16Dose/ScheduleModificationsforaSubject16CriteriaforDiscontinuationofStudyIntervention/ProductforWithdrawalofaSubject(oraCohort)16AssessmentofSafety18SpecificationofSafetyParameters18MethodsandTimingforAssessing,Recording,andAnalyzingSafetyParameters18AdverseEvents,Reactogenicity(forVaccineStudies),SeriousAdverseEvents.18ReportingProcedures20SeriousAdverseEventDetectionandReporting20ReportingofPregnancy21ProcedurestobeFollowedintheEventofAbnormalLaboratoryTestValuesorAbnormalClinicalFindings21TypeandDurationoftheFollow-upofSubjectsAfterAdverseEvents21HaltingRules21ClinicalMonitoringStructure23SiteMonitoringPlan23StatisticalConsiderations24Introduction24OverviewandStudyObjectives24StudyPopulation24StudyDesign24StudyOutcomeMeasures25StudyHypotheses25SampleSizeConsiderations25ParticipantEnrollmentandFollow-Up26PlannedInterimAnalyses(ifplanned)26SafetyReview26ImmunogenicityorEfficacyReview27FinalAnalysisPlan27SourceDocumentsandAccesstoSourceData/Documents28QualityControlandQualityAssurance29Ethics/ProtectionofHumanSubjects30DeclarationofHelsinki30InstitutionalReviewBoard30InformedConsentProcess30InformedConsent/AssentProcess(inCaseofaMinor)31ExclusionofWomen,Minoritie
网站客服QQ:2055934822
金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号